Non-small cell lung cancer: an overview of current management (Q40912868)

24 September 2017

1 reference

title

Non-small cell lung cancer: an overview of current management (English)

1 reference

24 September 2017

Dancey J

1

1 reference

24 September 2017

Le Chevalier T

series ordinal

2

1 reference

24 September 2017

publication date

1 January 1997

1 reference

European Journal of Cancer

24 September 2017

published in

1 reference

24 September 2017

volume

33 Suppl 1

1 reference

24 September 2017

page(s)

S2-7

1 reference

Mortality Patterns and Trends for Lung Cancer and Other Tobacco-Related Cancers in the Americas, 1955–1989

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

New directions for chemotherapy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

A new international staging system for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Epidemiology, screening, and prevention of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Mortality from tobacco in developed countries: indirect estimation from national vital statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Mortality of a cohort of French uranium miners exposed to relatively low radon concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

A mortality study of workers at seven beryllium processing plants

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Mortality from lung cancer and cardiovascular diseases among stainless-steel producing workers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Patterns of Absolute Risk of Lung Cancer Mortality in Former Smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Lung cancer and passive smoking: reconciling the biochemical and epidemiological approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Somatic genetic changes in lung cancer and precancerous lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

The relationship of p53 immunostaining to survival in carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Induction chemotherapy for locally advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Randomized trial of neoadjuvant therapy for lung cancer: interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Inoperable non-small cell lung cancer: radiation with or without chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Radical Radiotherapy and Chemotherapy in Localized Inoperable Non-Small-Cell Lung Cancer: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Quality of life during chemotherapy in non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Cost-effectiveness analysis: sleeping with an enemy or a friend?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900325-5

7 January 2021

10.1016/S0959-8049(96)00325-5

Identifiers

DOI

1 reference

release_urzoo6fwhjbwnk46qfe73rnzwa

24 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/urzoo6fwhjbwnk46qfe73rnzwa

24 November 2022

mapped directly with Wikidata item

1 reference